Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation.

INTRODUCTION: A new cardiovascular risk (CVR) calculator that incorporates Lipoprotein(a) [Lp(a)] levels has recently been designed. AIMS: To estimate CVR using the new score and to identify the reduction in low-density lipoprotein cholesterol (LDL-C) or systolic blood pressure (SBP) necessary to balance the risk attributable to Lp(a). METHODS: CVR throughout life and at 10 years was estimated with the new score in patients in primary prevention, both considering and not considering the value of Lp(a). When the estimated risk considering Lp(a) levels exceeded the baseline risk, the reduction in LDL-C levels or SBP necessary to balance the risk attributable to Lp(a) was calculated. RESULTS: In total, 671 patients (mean age 54.2 years, 47.2% women) were included. Globally, 22.7% of the population had high Lp(a) values (> 50 mg/dL or > 125 nmol/L). When calculating CVR throughout life and considering the Lp(a) value, the global risk increased in 66.7% of cases (median 19.3%). Similar results were observed when we assessed the 10-year risk. The risk associated with Lp(a) could be completely compensated by decreasing LDL-C (average 21 mg/dL) or SBP (average 6.3 mmHg) in 79.2% and 74.7% of cases, respectively. CONCLUSION: When calculating the CVR with the new score, two-thirds and one-third of the population were bidirectionally recategorized as 'up' or 'down,' respectively. The decrease in LDL-C or SBP mitigated the increased risk caused by Lp(a) levels across a substantial proportion of patients.

Impact of COVID-19 vaccination in post-COVID cardiac complications.

BACKGROUND: After the acute infection, COVID-19 can produce cardiac complications as well as long-COVID persistent symptoms. Although vaccination against COVID-19 represented a clear reduction in both mortality and ICU admissions, there is very little information on whether this was accompanied by a decrease in the prevalence of post-COVID cardiac complications. The aim of this study was to analyze the relationship between COVID-19 vaccination and the prevalence of post-COVID cardiac injury assessed by echocardiogram, and long-COVID persistent cardiac symptoms. METHODS: All patients who consulted for post-COVID evaluation 14 days after discharge from acute illness were included. Patients with heart disease were excluded. The relationship between complete vaccination scheme (at least two doses applied with 14 days or more since the last dose) and pathological echocardiographic findings, as well as the relationship of vaccination with persistent long-COVID symptoms, were evaluated by multivariate analysis, adjusting for age, sex and clinical variables that would have shown significant differences in univariate analysis. RESULTS: From 1883 patients, 1070 patients (56.8%) suffered acute COVID-19 without a complete vaccination scheme. Vaccination was associated with lower prevalence of cardiac injury (1.35% versus 4.11%, adjusted OR 0.33; 95% CI 0.17-0.65, p=0.01). In addition, vaccinated group had a lower prevalence of persistent long-COVID symptoms compared to unvaccinated patients (10.7% versus 18.3%, adjusted OR 0.52; 95% CI 0.40-0.69, p<0.001). CONCLUSION: Vaccination against COVID-19 was associated with lower post-COVID cardiac complications and symptoms, reinforcing the importance of fully vaccinating the population.

Injuria cardíaca post- COVID19 y su relación con la gravedad del cuadro agudo, los síntomas persistentes y la vacunación / Cardiac Injury after COVID-19 and its Association with the Severity of the Acute Presentation, Persistent Symptoms and Vaccination

RESUMEN Introducción: La infección por COVID-19 se asocia a compromiso cardiovascular en su etapa aguda. La información sobre el compromiso cardíaco post-COVID es muy heterogénea, y la indicación de realizar estudios de imágenes cardíacas de forma rutinaria es aún controvertida. Asimismo, no existe información actualizada sobre el efecto que produjo la vacunación masiva en la incidencia de la injuria cardíaca post-COVID. Objetivos: Analizar la prevalencia de injuria cardíaca mediante ecocardiograma luego de la infección por COVID-19 y su asociación con la gravedad del cuadro agudo y con los síntomas persistentes post-COVID. Como objetivo secundario se exploró la relación de la prevalencia de injuria cardíaca con el inicio de la campaña de vacunación contra COVID-19 en la República Argentina. Material y métodos: Estudio analítico, observacional, prospectivo y unicéntrico. Se incluyeron todos los pacientes consecutivos que consultaron para realizar evaluación post-COVID. Se realizó ecocardiograma transtorácico en todos los pacientes. Se consideró la fecha de inicio de la campaña de vacunación (29/12/2020) para el análisis de los subgrupos pre y post vacunación. Resultados: Se incluyeron los primeros 1000 pacientes que consultaron al centro desde el 01/09/2020 al 01/09/2021. Treinta y nueve (3,9%) presentaron hallazgos patológicos en el ecocardiograma compatibles con injuria post-COVID, incluyendo disfunción ventricular izquierda (2,8%), derrame pericárdico (0,5%) y trastorno de motilidad parietal (0,6%), no conocidos previamente. Los pacientes que padecieron cuadros de COVID-19 agudo moderados o graves presentaron mayor prevalencia de trastornos de motilidad parietal (2,9% versus 0,3%, p = 0,001) y derrame pericárdico (2,9% versus 0,14%, p = 0,001) en comparación con aquellos con cuadros asintomáticos o leves, y esta asociación se mantuvo al ajustar por factores de riesgo cardiovascular y edad (OR 6,7; IC 95% 1,05-42,2, p = 0,04 y OR 25,1; IC 95% 2,1-304,9, p = 0,01 respectivamente). El 19,3% de los pacientes referían síntomas persistentes en la consulta post-COVID; en estos pacientes se observó mayor evidencia de disfunción ventricular izquierda nueva (8,3% vs 2,4%, p<0,005); no obstante, dicha asociación perdió significancia en el análisis multivariado. Respecto a la relación de la injuria cardíaca con el inicio de la vacunación, los 330 pacientes que se realizaron estudios de control post-COVID previamente al inicio de la campaña presentaron mayor prevalencia de injuria que los 670 pacientes luego de esta fecha (6,3% vs 2,7%, p = 0,006). Esta relación se mantuvo en el análisis multivariado (OR 0,35; IC95% 0,17-0,69). Conclusión: La prevalencia de injuria cardíaca evaluada mediante ecocardiograma luego de la infección por COVID-19 fue de 3,9%. Se observó una asociación significativa e independiente entre cuadros iniciales de mayor gravedad y hallazgos patológicos en el ecocardiograma en la etapa post-COVID, no así con los síntomas persistentes. Los pacientes que consultaron luego del inicio de la campaña de vacunación en Argentina presentaron menos prevalencia de injuria cardíaca en comparación con los pacientes de la primera ola.

ABSTRACT Background: COVID-19 is associated with cardiovascular involvement in the acute phase. The information about cardiac involvement after COVID-19 is heterogeneous, and the indication to routinely perform cardiac imaging tests is still controversial. There is no updated information on the effect mass vaccination has on the incidence of cardiac injury after COVID-19. Objectives: The primary objective of this study was to evaluate the prevalence of cardiac injury after COVID-19 by transthoracic echocardiography and its association with the severity of the acute phase and with persistent symptoms after recovery. The secondary objective was to explore the association of the prevalence of cardiac injury with the beginning of the vaccination campaign against COVID-19 in Argentina. Methods: We conducted an observational, single-center, and retrospective study. All the consecutive patients who consulted for post-COVID-19 evaluation were included. All the patients underwent transthoracic echocardiography. The date the vaccination campaign started (12/29/2020) was considered the cut-off point for the analysis of the pre-vaccination and postvaccination subgroups. Results: The first 1000 patients who consulted in our center between 09/01/2020 and 09/01/2021 were included. Thirty-nine patients (3.9%) had new abnormal echocardiographic findings suggestive of cardiac injury after COVID-19, including left ventricular dysfunction (2.8%), pericardial effusion (0.5%), and wall motion abnormalities (0.6%). Patients with moderate or severe acute COVID-19 presented a higher prevalence of wall motion abnormalities (2.9% versus 0.3%, p= 0.001) and pericardial effusion (2.9% versus 0.14%, p = 0.001) compared to those with asymptomatic or mild COVID-19 and this association remained after adjusting for cardiovascular risk factors and age (OR 6.7, 95% CI 1.05-4.2, p = 0.04, and OR 25.1, 95% 2.1-304.9, p = 0.01 respectively). The percentage of patients who reported persistent symptoms during consultation after COVID-19 was 19.3%, and they had higher evidence of new left ventricular dysfunction (8.3% vs. 2.4%, p < 0.005); however, this association lost significance on multivariate analysis. When the association of cardiac injury with the start of vaccination was considered, the 330 patients who underwent post-COVID assessment before the vaccination campaign started had a higher prevalence of injury than the 670 patients evaluated after this date (6.3% vs. 2.7%, p = 0.006). and this association persisted on multivariate analysis (OR 0.35; 95%CI 0.17-0.69). Conclusion: The prevalence of cardiac injury assessed by echocardiography after COVID-19 was 3.9%. There was a significant and independent association between the severe initial presentations and the abnormal echocardiographic findings after COVID-19, but not with persistent symptoms. Patients who consulted after the vaccination campaign started in Argentina had a lower prevalence of cardiac injury compared with those patients in the first wave.

Variable association of 24-h peripheral and central hemodynamics and stiffness with hypertension-mediated organ damage: the VASOTENS Registry.

OBJECTIVE: In this analysis of the telehealth-based Vascular health ASsessment Of The hypertENSive patients Registry, we checked how 24-h central and peripheral hemodynamics compare with hypertension-mediated organ damage (HMOD). METHODS: In 646 hypertensive patients (mean age 52 ±â€Š16 years, 54% males, 65% treated) we obtained ambulatory brachial and central SBP and pulse pressure (PP), SBP, and PP variability, pulse wave velocity and augmentation index with a validated cuff-based technology. HMOD was defined by an increased left ventricular mass index (cardiac damage, evaluated in 482 patients), an increased intima-media thickness (vascular damage, n = 368), or a decreased estimated glomerular filtration rate or increased urine albumin excretion (renal damage, n = 388). RESULTS: Ambulatory SBP and PPs were significantly associated with cardiac damage: the largest odds ratio was observed for 24-h central SBP [1.032 (1.012, 1.051), P = 0.001] and PP [1.042 (1.015, 1.069), P = 0.002], the weakest for brachial estimates. The association was less strong for vascular damage with a trend to the superiority of 24-h central [1.036 (0.997, 1.076), P = 0.070] over brachial PP [1.031 (1.000, 1.062), P = 0.052]. No statistically significant association was observed for renal damage. SBP and PP variabilities, pulse wave velocity and augmentation index were not associated with any form of HMOD. In the multivariate analysis, age was associated with any type of HMOD, whereas central SBP and PP were predictive of an increased risk of cardiac damage. CONCLUSION: In hypertensive patients a variable association exists between peripheral and central hemodynamics and various types of HMOD, with the most predictive power being observed for central SBP and PP for cardiac damage.

[Prevalence of pain among patients admitted to a clinical hospital]. / Prevalencia de dolor en la internación en un hospital de alta complejidad de Argentina.

BACKGROUND: Pain prevalence during hospital admission is variable, with estimates ranging from 32 to 77%. AIM: To determine pain prevalence during admission to a clinical hospital. MATERIAL AND METHODS: Patients admitted to medical and surgical wards were interrogated about the presence of pain within 48 to 72 hours after admission. Subjective pain was analyzed using a scale ranging from 0 to 10. Data was analyzed separately for medical, surgical, and obstetrical patients. RESULTS: A total of 736 patients aged 18 to 94 years (416 women) were recruited. Pain prevalence at 48 hours after admission was 56% (95% confidence intervals (CI (52.7 to 60.1). Pain prevalence in medical, surgical and obstetric patients was 37% (95% CI 31.4 to 42.1), 70% (95% CI 64.5 to 75.5) and 77% (95% CI 68.6 to 84), respectively. The median pain intensities in medical, surgical, and obstetrical patients were 7 (interquartile range (IQR) 6-8), 7 (IQR 5-8) y 7 (IQR 5-8), respectively. CONCLUSIONS: The prevalence of pain among patients admitted to the hospital is high, especially in obstetric and surgical units.

Prevalencia de dolor en la internación en un hospital de alta complejidad de Argentina / Prevalence of pain among patients admitted to a clinical hospital

Background: Pain prevalence during hospital admission is variable, with estimates ranging from 32 to 77%. Aim: To determine pain prevalence during admission to a clinical hospital. Material and Methods: Patients admitted to medical and surgical wards were interrogated about the presence of pain within 48 to 72 hours after admission. Subjective pain was analyzed using a scale ranging from 0 to 10. Data was analyzed separately for medical, surgical, and obstetrical patients. Results: A total of 736 patients aged 18 to 94 years (416 women) were recruited. Pain prevalence at 48 hours after admission was 56% (95% confidence intervals (CI (52.7 to 60.1). Pain prevalence in medical, surgical and obstetric patients was 37% (95% CI 31.4 to 42.1), 70% (95% CI 64.5 to 75.5) and 77% (95% CI 68.6 to 84), respectively. The median pain intensities in medical, surgical, and obstetrical patients were 7 (interquartile range (IQR) 6-8), 7 (IQR 5-8) y 7 (IQR 5-8), respectively. Conclusions: The prevalence of pain among patients admitted to the hospital is high, especially in obstetric and surgical units.

Ambulatory blood pressure and arterial stiffness web-based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry.

The VASOTENS Registry is an international telehealth-based repository of 24-hour ambulatory blood pressure monitorings (ABPM) obtained through an oscillometric upper-arm BP monitor allowing combined estimation of some vascular biomarkers. The present paper reports the results obtained in 1200 participants according to different categories of CV risk. Individual readings were averaged for each recording and 24-hour mean of brachial and aortic systolic (SBP) and diastolic blood pressure (DBP), pulse wave velocity (PWV), and augmentation index (AIx) obtained. Peripheral and central BP, PWV and AIx values were increased in older participants (SBP only) and in case of hypertension (SBP and DBP). BP was lower and PWV and AIx higher in females. PWV was increased and BP unchanged in case of metabolic syndrome. Our results suggest that ambulatory pulse wave analysis in a daily life setting may help evaluate vascular health of individuals at risk for CV disease.

Tasa de reinternaciones y factores asociados en ancianos luego de una internación por fractura de cadera / Rate of re-experiences and associated factors in the elderly after hospitalization due to hip fracture

INTRODUCCIÓN: El anciano con fractura de cadera tiene alto riesgo de complicaciones y mortalidad hospitalaria. Las estadías hospitalarias cortas y el alta temprana con problemas clínicos activos pueden llevar a reinternaciones. OBJETIVOS: conocer la tasa de reinternaciones, los motivos y las variables predictoras de las mismas en los sujetos que tuvieron fracturas de cadera. MÉTODOS: Se trabajó una cohorte retrospectiva. Se incluyó a todos los pacientes ingresados en el Registro Institucional de Ancianos con Fractura de Cadera entre julio de 2014 y julio de 2017. Se describió la tasa de reinternación y su IC95%. Se utilizó un modelo de riesgo proporcional de Cox para describir factores de riesgo y el tiempo a la reinternación. RESULTADOS: Se incluyó a 858 pacientes. La mediana de días de internación fue de 6 (rango intercuartil [RIC 5-9]). El 86% (737) de los pacientes era de sexo femenino, con una mediana de edad de 86 años (RIC 81-89). La tasa de reinternación a los 30 días fue de 10% (IC95%: 8,3-12,5) y al año, de 39% (IC95%: 34,8-42,6). La principal causa fue la infección (30%). Los factores asociados fueron: edad (>85 años) Razón de Hazard o Hazard ratio (HR)1,3 (IC95%: 1-1,7; p 0,03), sexo femenino HR 0,5 (IC95%: 0,4-0,7; p<0,01), fragilidad HR 1,4 (IC95%: 1,1-1,8; p<0,01), score de Charlson (≥2) HR 1,6 (IC95%: 1,3-2,1; p<0,01), días de internación (>7 días) HR 1,4 (IC95%: 1,2-1,9; p<0,01). CONCLUSIONES: La reinternación después de una fractura de cadera tiene alta incidencia. El cuidado perioperatorio de los pacientes con fractura de cadera es esencial para reducir las complicaciones.

INTRODUCTION: Elderly patients with hip fracture are at high risk for complications and in-hospital mortality. Short hospital stay and early discharge with still active clinical problems may lead to readmissions. OBJECTIVES: to know the rate of readmissions, the reasons and the predictive variables in patients who had hip fractures. METHODS: A retrospective cohort study was performed, with all patients included in the institutional registry of elderly patients with hip fracture between July 2014 and July 2017. Readmission rates and their CI95% were described. A proportional risk Cox model was used to describe risk factors and time-toreadmission. RESULTS: A total of 858 patients were included with a median hospital stay of 6 days (interquartile range [IQR] 5-9), 86% (737) of female patients and a median age of 86 years (IQR 81-89). Readmission rates were 10% (CI95%: 8.3-12.5) at 30 days and 39% (CI95%: 34.8-42.6) at 12 months. The main cause was infection (30%). Associated factors were: age (>85 years) HR 1.3 (CI95%: 1-1.7; p 0.03), female gender HR 0.5 (CI95%: 0.4-0.7; p<0.01), fragility HR 1.4 (CI95%: 1.1-1.8; p<0.01), Charlson score (≥2) HR 1.6 (CI95%: 1.3-2.1; p<0.01), hospital stay (>7 days) HR 1.4 (CI95%: 1.2- 1.9, p<0.01). CONCLUSIONS: Readmission after hip fracture has a high incidence. Perioperative care of patients with hip fracture is essential to reduce complications.

Mean platelet volume as a prognostic factor for venous thromboembolic disease.

BACKGROUND: Mean platelet volume (MPV) is a risk factor for cardiovascular and inflammatory diseases. AIM: To evaluate the association between high MPV and 90-day mortality after an episode of venous thromboembolism (VTE). MATERIAL AND METHODS: Retrospective cohort of 594 patients with a median age of 73 years (58% women) with a first episode VTE, included in an institutional Thromboembolic Disease registry between 2014 and 2015. MPV values were obtained from the automated blood cell count measured at the moment of VTE diagnosis. Volumes ≥ 11 fL were classified as high. All patients were followed for 90 days to assess survival. RESULTS: The main comorbidities were cancer in 221 patients (37%), sepsis in 172 (29%) and coronary artery disease in 107 (18%). Median MPV was 8 fl (8-9), brain natriuretic peptide 2,000 pg/ml (1,025-3,900) and troponin 40 pg/ml (19.5-75). Overall mortality was 20% (121/594) during the 90 days of follow-up. Thirty three deaths occurred within 7 days and 43 within the first month. The loss of patients from follow-up was 5% (28/594) at 90 days. Mortality among patients with high MP was 36% (23/63). The crude mortality hazard ratio (HR) for high MPV was 2.2 (95% confidence intervals (CI) 1.4-3.5). When adjusted for sepsis, oncological disease, heart disease, kidney failure and surgery, the mortality HR of high MPV was 2.4 (CI95% 1.5-3.9) in the VTE group, 2.3 (CI95% 1.5-4.4) in the deep venous thrombosis group, and 2.9 (CI95% 1.6 -5.6) in the pulmonary embolism group. CONCLUSIONS: High MPV is an independent risk factor for mortality following an episode of VTE.

Comparing Office, Central, Home and Ambulatory Blood Pressure in Predicting Left Ventricular Mass / Comparación entre presión arterial de consultorio, central, domiciliaria y ambulatoria para predecir masa ventricular izquierda

The blood pressure measurement method that more accurately predicts a left ventricular mass is controversial, and the evidence suggesting superiority of central over brachial measurements is contradictory. The aim of this study was to compare the relationship between the different clinic and out-of-clinic blood pressure measurements methods with left ventricular mass in patients who attended a specialised hypertension centre for a central blood pressure measurement. An analysis was performed on the correlations between left ventricular mass and central and brachial blood pressure measurements made in the clinic, and home, as well as 24-h systolic blood pressure measurements. A linear regression analysis was then performed to assess the independent relationship of each blood pressure measurement with left ventricular mass. The results on 824 treated and 123 untreated patients showed no significant differences between correlations, although home readings tended to have the best correlations. In regression adjusted models, for each 10 mmHg increase in systolic home blood pressure the left ventricular mass increased 10 g/m2 (95% CI; 3.7-27, p=.01, adjR2 0.38), and for 24-h ambulatory systolic blood pressure it increased 2.3 g/m2 (95% CI 0.76-3.9, p<.01, adjR2 0.15) in treated and untreated patients, respectively. The association of systolic blood pressure with left ventricular mass was better explained by home and 24-h ambulatory monitoring than to clinic-based measurements in treated and untreated patients, respectively. In the clinic, however, the central measurement was not superior to brachial blood pressure

Existe controversia sobre qué método de medición de presión arterial predice más precisamente la masa ventricular izquierda. La evidencia que sugiere superioridad de las mediciones centrales sobre las braquiales resulta contradictoria. Nuestro objetivo fue comparar la asociación de diferentes formas de medir la presión dentro y fuera del consultorio con masa ventricular izquierda en pacientes que asistieron a un centro especializado en hipertensión a medirse la presión central. Analizamos las correlaciones entre masa ventricular izquierda y presión sistólica a nivel central y braquial en consultorio, en el domicilio y ambulatoria de 24h. Luego realizamos un análisis de regresión lineal para evaluar la asociación independiente de cada método con la masa ventricular izquierda. Como resultado, en 824 pacientes tratados y 123 no tratados las diferencias entre correlaciones no fueron significativas, aunque las lecturas tomadas fuera del consultorio tuvieron mejores asociaciones. En los modelos ajustados, por cada 10mmHg de aumento en la presión sistólica domiciliaria la masa ventricular aumentó 10g/m2 (IC 95%: 3,7-27; p=0,01; R2aj: 0,38), y para la presión sistólica ambulatoria de 24h aumentó 2,3g/m2 (IC 95%: 0,76-3,9; p<0,01; R2aj: 0,15) en pacientes tratados y no tratados, respectivamente. La asociación de la presión arterial sistólica con masa ventricular izquierda fue explicada mejor por el monitoreo domiciliario y ambulatorio de 24h, más que con las mediciones de consultorio en pacientes tratados y no tratados, respectivamente. En el consultorio, sin embargo, la presión central no fue superior a la braquial

Mean platelet volume as a prognostic factor for venous thromboembolic disease / Volumen plaquetario medio como factor pronóstico de la enfermedad tromboembólica venosa

ABSTRACT Background: Mean platelet volume (MPV) is a risk factor for cardiovascular and inflammatory diseases. Aim: To evaluate the association between high MPV and 90-day mortality after an episode of venous thromboembolism (VTE). Material and Methods: Retrospective cohort of 594 patients with a median age of 73 years (58% women) with a first episode VTE, included in an institutional Thromboembolic Disease registry between 2014 and 2015. MPV values were obtained from the automated blood cell count measured at the moment of VTE diagnosis. Volumes ≥ 11 fL were classified as high. All patients were followed for 90 days to assess survival. Results: The main comorbidities were cancer in 221 patients (37%), sepsis in 172 (29%) and coronary artery disease in 107 (18%). Median MPV was 8 fl (8-9), brain natriuretic peptide 2,000 pg/ml (1,025-3,900) and troponin 40 pg/ml (19.5-75). Overall mortality was 20% (121/594) during the 90 days of follow-up. Thirty three deaths occurred within 7 days and 43 within the first month. The loss of patients from follow-up was 5% (28/594) at 90 days. Mortality among patients with high MP was 36% (23/63). The crude mortality hazard ratio (HR) for high MPV was 2.2 (95% confidence intervals (CI) 1.4-3.5). When adjusted for sepsis, oncological disease, heart disease, kidney failure and surgery, the mortality HR of high MPV was 2.4 (CI95% 1.5-3.9) in the VTE group, 2.3 (CI95% 1.5-4.4) in the deep venous thrombosis group, and 2.9 (CI95% 1.6 −5.6) in the pulmonary embolism group. Conclusions: High MPV is an independent risk factor for mortality following an episode of VTE.

Antecedentes: El volumen plaquetario medio (VPM) es un factor de riesgo de complicaciones cardiovasculares y enfermedades inflamatorias. Objetivo: Evaluar la asociación entre VPM alto y la mortalidad a los 90 días después de un episodio de tromboembolismo venoso (ETV). Material y Métodos: Cohorte retrospectiva de 594 pacientes adultos con una edad media de 73 años (58% mujeres) con un primer episodio de ETV incluidos en un registro de enfermedad tromboembólica institucional entre 2014 y 2015. Se obtuvieron valores de VPM desde el hemograma tomado en el momento del diagnóstico de ETV y un volumen ≥ 11 fL fue clasificado como alto. Todos los pacientes fueron seguidos durante 90 días para determinar sobrevida. Resultados: Las comorbilidades fueron cáncer en 221 pacientes (37%), sepsis en 172 (29%) y enfermedad coronaria en 107 (18%). La mediana de VPM fue 8 fl (89), el péptido natriurético cerebral fue de 2.000 pg/ml (1.025-3.900) y la troponina fue de 40 pg/ml (19,5-75). La mortalidad global a 90 días fue 20% (121/594). Treinta y tres muertes ocurrieron dentro de los 7 días y 43 en el primer mes. La pérdida de seguimiento de pacientes fue de 5% (28/594) a los 90 días. La mortalidad en el grupo con VPM alto fue 36% (23/63). La razón de riesgo (HR) cruda de la mortalidad para un VPM alto fue de 2,2 (intervalos de confianza (IC) de 95% 1,4-3,5). Cuando se ajustó por sepsis, enfermedad oncológica, enfermedad cardíaca, insuficiencia renal y cirugía, la HR de muerte para un VPM alto fue de 2,4 (IC95% 1,5-3,9) en el grupo de ETV; 2,3 (IC95% 1,5-4,4) en el grupo de trombosis venosa profunda; y 2,9 (CI95% 1,6 −5,6) en el grupo de embolia pulmonar. Conclusiones: Un VPM alto es un factor de riesgo independiente de mortalidad después de un episodio de ETV.

Comparing Office, Central, Home and Ambulatory Blood Pressure in Predicting Left Ventricular Mass.

The blood pressure measurement method that more accurately predicts a left ventricular mass is controversial, and the evidence suggesting superiority of central over brachial measurements is contradictory. The aim of this study was to compare the relationship between the different clinic and out-of-clinic blood pressure measurements methods with left ventricular mass in patients who attended a specialised hypertension centre for a central blood pressure measurement. An analysis was performed on the correlations between left ventricular mass and central and brachial blood pressure measurements made in the clinic, and home, as well as 24-h systolic blood pressure measurements. A linear regression analysis was then performed to assess the independent relationship of each blood pressure measurement with left ventricular mass. The results on 824 treated and 123 untreated patients showed no significant differences between correlations, although home readings tended to have the best correlations. In regression adjusted models, for each 10 mmHg increase in systolic home blood pressure the left ventricular mass increased 10 g/m2 (95% CI; 3.7-27, p=.01, adjR2 0.38), and for 24-h ambulatory systolic blood pressure it increased 2.3 g/m2 (95% CI 0.76-3.9, p<.01, adjR2 0.15) in treated and untreated patients, respectively. The association of systolic blood pressure with left ventricular mass was better explained by home and 24-h ambulatory monitoring than to clinic-based measurements in treated and untreated patients, respectively. In the clinic, however, the central measurement was not superior to brachial blood pressure.

Prevalence and related factors of office and home hypotension in older treated hypertensive patients.

BACKGROUND: Older hypertensive adults under treatment are especially susceptible to hypotensive episodes, which entail an elevated risk. However, data on this subject are very scarce. AIM: The purpose of this study was to determine the prevalence and predictors of office and home hypotension in older (≥ 65 years) treated hypertensive adults. METHODS: Blood pressure (BP) was measured at the office and at home, using a validated oscillometric device. Office and home hypotension were defined as systolic BP (SBP) < 110 and/or diastolic BP (DBP) < 70 mmHg, and SBP < 105 and/or DBP < 65 mmHg, respectively. Masked hypotension was considered when office BP ≥ 110/70 and home BP < 105 and/or < 65 mmHg. We evaluated factors associated with hypotension both at the office and at home through multivariable models. RESULTS: The prevalence of hypotension among the 302 patients included in the study was 29.8% at the office and 23.9% at home, whereas the prevalence of masked hypotension was 10.4%. Older age, lower body mass index and use of calcium channel blockers were associated with office hypotension, while older age, diabetes and ischemic heart disease were predictors for home hypotension. CONCLUSION: Hypotension is frequent in older hypertensive adults under treatment. The presence of diabetes, ischemic heart disease and older age should alert for screening of hypotension at home to avoid overtreatment.

MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol.

INTRODUCTION: Masked uncontrolled hypertension (MUCH) carries an increased risk of cardiovascular (CV) complications and can be identified through combined use of office (O) and ambulatory (A) blood pressure (BP) monitoring (M) in treated patients. However, it is still debated whether the information carried by ABPM should be considered for MUCH management. Aim of the MASked-unconTrolled hypERtension management based on OBP or on ambulatory blood pressure measurement (MASTER) Study is to assess the impact on outcome of MUCH management based on OBPM or ABPM. METHODS AND ANALYSIS: MASTER is a 4-year prospective, randomised, open-label, blinded-endpoint investigation. A total of 1240 treated hypertensive patients from about 40 secondary care clinical centres worldwide will be included -upon confirming presence of MUCH (repeated on treatment OBP <140/90 mm Hg, and at least one of the following: daytime ABP ≥135/85 mm Hg; night-time ABP ≥120/70 mm Hg; 24 hour ABP ≥130/80 mm Hg), and will be randomised to a management strategy based on OBPM (group 1) or on ABPM (group 2). Patients in group 1 will have OBP measured at 0, 3, 6, 12, 18, 24, 30, 36, 42 and 48 months and taken as a guide for treatment; ABPM will be performed at randomisation and at 12, 24, 36 and 48 months but will not be used to take treatment decisions. Patients randomised to group 2 will have ABPM performed at randomisation and all scheduled visits as a guide to antihypertensive treatment. The effects of MUCH management strategy based on ABPM or on OBPM on CV and renal intermediate outcomes (changing left ventricular mass and microalbuminuria, coprimary outcomes) at 1 year and on CV events at 4 years and on changes in BP-related variables will be assessed. ETHICS AND DISSEMINATION: MASTER study protocol has received approval by the ethical review board of Istituto Auxologico Italiano. The procedures set out in this protocol are in accordance with principles of Declaration of Helsinki and Good Clinical Practice guidelines. Results will be published in accordance with the CONSORT statement in a peer-reviewed scientific journal. TRIAL REGISTRATION NUMBER: NCT02804074; Pre-results.

[Direct medical costs of hospitalization due to heart failure in the health plan of the Hospital Italiano de Buenos Aires.] / Costos médicos directos de las Internaciones por Insuficiencia Cardiaca en el Plan de Salud del Hospital Italiano de Buenos Aires.

Introduction: It is undeniable that costs of medical care in chronic diseases has increased. There are multiple reasons: population aging, associated pathologies late complications, available high cost health technologies. Heart failure is one of the main causes of global death and morbidity, being the final consequence of cardiac diseases and hypertension, fulfilling criteria of becoming a high costs pathology. We are going to evaluate direct medical costs of hospitalization due to heart failure from the vision of those who manage health resources. Materials and Methods: Observational, retrospective cohort using secondary databases from the Hospital Italiano de Buenos Aires. Adult population with diagnosed heart failure that required hospitalization with discharge diagnosis of heart failure between 2007 and 2011. Results: The main cost component was attributable to hospital bed, diagnostic and therapeutic interventions. The average incidence of hospitalizations during the period was 11.4 per 10,000 patients / year. Overall mortality in the episode rate was 0.25% per year and 28.8 % overall 60% Conclusion: The most important decision seems decide whether management can be done on an outpatient basis or not, using heart failures guidelines to optimize time of admission, auxiliary diagnostic methods and medications used.

Introducción: Es innegable el incremento de los costos de los cuidados médicos de las enfermedades crónicas. Existen múltiples razones: envejecimiento poblacional, complicaciones tardías de las patologías asociadas y disponibilidad de tecnologías sanitarias de alto costo. La insuficiencia cardiaca es una de las principales causas mundiales de mortalidad y morbilidad, siendo la consecuencia final de las enfermedades cardíacas y la hipertensión arterial, cumpliendo criterios para convertirse en una patología de gran consumo de recursos. En el presente trabajo estudiaremos los costos de la insuficiencia cardiaca desde la visión de quienes gestionan los recursos sanitarios. Materiales y Métodos: Estudio observacional, de cohorte retrospectiva utilizando bases de datos secundarias del Plan de Salud del Hospital Italiano de Buenos Aires. Población adulta con diagnóstico de insuficiencia cardiaca que hayan requerido internación con diagnóstico al egreso de insuficiencia cardiaca entre los años 2007 y 2011.ResultadosEl principal componente de los costos fue atribuible a la estadía hospitalaria, las intervenciones diagnósticas y terapéuticas. La incidencia media de internaciones durante el período fue de 11.4 por cada 10.000 pacientes/año. La mortalidad global en el episodio índice fue del 0,25%, al año 28,8% y global del 60%ConclusiónLa decisión más importante parece ser decidir si el manejo puede hacerse ambulatoriamente o no, poniendo en marcha guías de manejo de la insuficiencia cardiaca para optimizar tiempos de internación, métodos auxiliares de diagnóstico y los medicamentos utilizados. Resultados: El principal componente de los costos fue atribuible a la estadía hospitalaria, las intervenciones diagnósticas y terapéuticas. La incidencia media de internaciones durante el período fue de 11.4 por cada 10.000 pacientes/año. La mortalidad global en el episodio índice fue del 0,25%, al año 28,8% y global del 60% Conclusión: La decisión más importante parece ser decidir si el manejo puede hacerse ambulatoriamente o no, poniendo en marcha guías de manejo de la insuficiencia cardiaca para optimizar tiempos de internación, métodos auxiliares de diagnóstico y los medicamentos utilizados.

Hemodynamic characterization of hypertensive patients with an exaggerated orthostatic blood pressure variation.

Exaggerated orthostatic blood pressure variation (EOV) is a poorly understood phenomenon related to high cardiovascular risk. We aimed to determine whether hypertensive patients with EOV have a distinct hemodynamic pattern, assessed through impedance cardiography. METHODS: In treated hypertensive patients, we measured the cardiac index (CI), systemic vascular resistance index (SVRI), blood pressure (BP), and heart rate (HR) in the supine and standing (after 3 minutes) positions, defining three groups according to BP variation: 1) Normal orthostatic BP variation (NOV): standing systolic BP (stSBP)-supine systolic BP (suSBP) between -20 and 20 mmHg and standing diastolic BP (stDBP)-supine diastolic BP (suDBP) between -10 and 10 mmHg; 2) orthostatic hypotension (OHypo): stSBP-suSBP≤-20 or stDBP-suDBP≤-10 mmHg; 3) orthostatic hypertension (OHyper): stSBP-suSBP≥20 or stDBP-suDBP≥10 mmHg. We performed multivariable analyses to determine the association of hemodynamic variables with EOV. RESULTS: We included 186 patients. Those with OHyper had lower suDBP and higher orthostatic SVRI variation compared to NOV. In multivariable analyses, orthostatic HR variation (OR = 1.06 (95%CI 1.01-1.13), p = 0.03) and orthostatic SVRI variation (OR = 1.16 (95%CI 1.06-1.28), p = 0.002) were independently related to OHyper. No variables were independently associated with OHypo. CONCLUSION: Patients with OHyper have a distinct hemodynamic pattern, with an exaggerated increase in SVRI and HR when standing.

Validation of a new piezoelectric device for noninvasive measurement of central aortic systolic blood pressure.

OBJECTIVE: The objective of this study was to compare the aortic piezoelectric device for noninvasive measurement of central aortic systolic blood pressure (cSBP) with the SphygmoCor. PARTICIPANTS AND METHODS: A total of 85 participants from both sexes, aged 18-80 years, were stratified into three age groups (<30, 30-60, >60 years), with an equal number of healthy volunteers and hypertensive patients. We performed three cSBP measurements with each device, in an alternate manner, using the Bland-Altman method to determine the level of agreement. The standard of the Association for the Advancement of Medical Instrumentation for brachial blood pressure evaluation was used for the comparison. RESULTS: The mean cSBPs were 109.3±12.05 and 109.0±12.2 mmHg with the SphygmoCor and the Aortic device, respectively, showing a strong correlation (r=0.98, P<0.001). A mean difference of 0.35±2.43 mmHg (95% confidence interval: 0.17-0.87, P=NS) was obtained with the Bland-Altman method. The 95% limits of agreement was -4.4 to +5.1 mmHg. CONCLUSION: Complying with the Association for the Advancement of Medical Instrumentation criteria, cSBP measurements obtained with the Aortic and the SphygmoCor devices are equivalent.

Perspectiva clínica sobre el tratamiento antihipertensivo en adultos con hipertensión grado 1 y riesgo cardiovascular bajo a moderado: consulta internacional de expertos

[RESUMEN]. La hipertensión arterial es el principal factor de riesgo de la carga global de las enfermedades. Una pregunta en debate es si la hipertensión arterial grado 1 (140–159/90–99 mm Hg) con riesgo cardiovascular (RCV) total bajo (mortalidad cardiovascular < 1% a los 10 años) a moderado (mortalidad cardiovascular > 1% y < 5% a los 10 años) debe ser tratada con agentes antihipertensivos. Un proceso de consulta virtual internacional fue realizado para resumir las opiniones de los expertos seleccionados. Después del análisis holístico de todos los elementos epidemiológicos, clínicos, psicosociales y de salud pública, este proceso de consulta llegó al siguiente consenso para adultos hipertensos < 80 años de edad: 1) La interrogante, de si el tratamiento medicamentoso en la hipertensión grado 1 debe ser precedido por un periodo de algunas semanas o meses, durante el cual solo se recomienden medidas sobre el estilo de vida no está basada en evidencia, pero el consenso de opinión es reservar un periodo para solo cambios en el estilo de vida únicamente en los pacientes con hipertensión grado 1 “aislada” (hipertensión grado 1 no complicada con RCV total absoluto bajo, y sin otros factores de RCV mayores ni modificadores del riesgo). 2) El inicio del tratamiento antihipertensivo medicamentoso en pacientes con hipertensión grado 1 y RCV absoluto moderado no debe demorarse. 3) Los hombres ≥ 55 años y las mujeres ≥ 60 años con hipertensión grado 1 no complicada deben ser automáticamente clasificados dentro de la categoría de RCV total absoluto moderado, incluso en ausencia de otros factores de riesgo mayores y modificadores del riesgo. 4) Las estatinas deben tenerse en cuenta junto con la terapia antihipertensiva, independientemente de los valores de colesterol, en pacientes con hipertensión grado 1 y RCV moderado.

[ABSTRACT]. Hypertension is a leading risk factor for disease burden globally. An unresolved question is whether grade 1 hypertension (140-159/90-99 mmHg) with low (cardiovascular mortality < 1% at 10 years) to moderate (cardiovascular mortality > 1% and < 5% at 10 years) absolute total cardiovascular risk (CVR) should be treated with antihypertensive agents. A virtual international consultation process was undertaken to summarize the opinions of select experts. After holistic analysis of all epidemiological, clinical, psychosocial, and public health elements, this consultation process reached the following consensus in hypertensive adults aged < 80 years: (1) The question of whether drug treatment in grade 1 should be preceded by a period of some weeks or months during which only life style measures are recommended cannot be evidence based, but the consensus opinion is to have a period of lifestyle alone reserved only to patients with grade 1 “isolated” hypertension (grade 1 uncomplicated hypertension with low absolute total CVR, and without other major CVR factors and risk modifiers). (2)The initiation of antihypertensive drug therapy in grade 1 hypertension with moderate absolute total CVR should not be delayed. (3) Men ≥ 55 years and women ≥ 60 years with uncomplicated grade1 hypertension should automatically be classified within the moderate absolute total CVR category, even in the absence of other major CVR factors and risk modifiers. (4) Statins should be considered along with blood-pressure lowering therapy, irrespective of cholesterol levels, in patients with grade 1 hypertensive with moderate CVR.

[Extremely elevated erythrosedimentation in an adult population in the City of Buenos Aires]. / Eritrosedimentación extremadamente elevada en una población de adultos en la ciudad de Buenos Aires.

BACKGROUND: An extremely elevated erythrosedimentation rate (ESR), defined as equal or higher than 100 mm/h, has been linked to serious underlying conditions, such as infections, connective tissue and oncologic disease. AIM: To analyze a group of patients in order to determine the underlying diagnosis and the characteristics associated with extremely elevated ESR in our environment. METHODS: Cross-sectional study of adult patients, who presented with at least one ESR equal or higher than 100 mm/h at Hospital Italiano, in Buenos Aires (Buenos Aires, Argentina) between January 2002 and August 2014. RESULTS: During the previously stated period of time, we analyzed the results of 879 patients. All patients were over 18 years of age. The median for the ESR results was 111 mm/h (interquartile range 105-120). The most prevalent etiology of an elevated ESR was infectious (41.64%), followed by malignancies (21.62%) and autoimmune / inflammatory diseases (12.97%). The most frequent individual diagnosis found was pneumonia (11.49%), followed by undetermined causes (5.92%). CONCLUSION: When comparing inpatient versus outpatient populations, the most frequent cause was infectious in the former group, while malignancies were the most frequent diagnosis in the latter.

[Analysis of Crowding in an Adult Emergency Department of a tertiary university hospital]. / Descripción de las características del fenómeno Crowding en la Central de Emergencia de Adultos, en un hospital universitario de alta complejidad: estudio de cohorte retrospectiva.

BACKGROUND: Crowding in Emergency Departments (ED), results from the imbalance between the simultaneous demand for health care and the ability of the system to respond. The NEDOCS scale (National Emergency Department Crowding Scale) measures the degree of crowding in an ED. AIM: To describe ED Crowding characteristics, using the NEDOCS scale, in an Argentinean hospital. MATERIAL AND METHODS: A retrospective cohort study was conducted with all adult patient consultations between July 2013 and July 2014 at the ED of Hospital Italiano de Buenos Aires. We included all hours in the analysis period (365 days x 24 h = 8,760). The NEDOCS value was calculated for each hour using an automatic algorithm and was quantified in a six points score. Levels 4 (overcrowded), 5 (severely overcrowded) and 6 (dangerously overcrowded) were defined as overcrowding. Contour plots analysis was applied to identify patterns. RESULTS: During the study period, 124,758 visits to the ED were registered. Overcrowding was present in 57.7% (5,055) of the analyzed hours. A predominance of scores between four and five was observed between 10:00 and 24:00 hours. The months with predominance of overcrowding were June, July and August (southern winter). CONCLUSIONS: The calculation of the NEDOCS score and the analysis of its temporal distribution are highly relevant to identify opportunities for improvement and to develop mechanisms to prevent the highest categories of overcrowding.